6-MBPB

6-MBPB, also known as 6-benzofuran, is a monoamine releasing agent and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families. It is a positional isomer of 5-MBPB.
The drug appears to act as a serotonin–norepinephrine–dopamine releasing agent. The values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB. In the case of -6-MBPB, they were 54nM for serotonin, 77nM for norepinephrine, and 41nM for dopamine, whereas for -6-MBPB, they were 172nM for serotonin, 227nM for norepinephrine, and inactive for dopamine. Hence, -6-MBPB is an SNDRA, whereas -MBPB is a serotonin–norepinephrine releasing agent. The enantiomers showed a mixed profile of acting as full versus partial releasers. Unlike 5-MAPB, it is a relatively weak serotonin 5-HT_1B receptor agonist. 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.
Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021. It was first described in the scientific literature by 2022. 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.